Trailing-twelve-month (TTM) revenue is $6.51 Billion with a year-over-year growth of +14.55%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $1,553,100,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $1,569,600,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-25 |
| Q1 FY2026Period ended 2026-03-31 | $1,648,600,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $1,741,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $6,512,300,000 |
Current P/S: $49,685,782,000 market capitalization ÷ $6,512,300,000 TTM revenue = 7.63x.
Market capitalization source: FMP quote. Quote observed 2026-09-25T20:00:03.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $1.74B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-26T00:15:44.311Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Critical Care | $725M | $835M | $855M | $928M | N/A | N/A |
| Surgical Heart Valve Therapy | $762M | $889M | $893M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Europe | $974M | $1.2B | $1.2B | $1.3B | $1.3B | $1.5B |
| JAPAN | $460M | $529M | $474M | $452M |
$6.51B
$6.51 Billion
+14.55%
vs. $5.69B a year ago (TTM)
+5.75%
5 Year compound annual growth rate
1 Year
+14.55%
3 Year
+6.29%
5 Year
+5.75%
10 Year
+9.03%
15 Year
+9.92%
20 Year
+9.74%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $6.07B | +$628.10M | +11.55% |
| 2024 | $5.44B | +$429.50M | +8.57% |
| 2023 | $5.01B | ($372.40M) | (6.92%) |
| 2022 | $5.38B | +$149.90M | +2.86% |
| 2021 | $5.23B | +$846.20M | +19.29% |
| 2020 |
TTM Growth
+14.55%
3-Year CAGR
+6.29%
5-Year CAGR
+5.75%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-26T00:15:44.311Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $999M |
| $981M |
| $1.0B |
| Transcatheter Heart Valves | $2.9B | $3.4B | $3.5B | $3.9B | $4.1B | $4.5B |
|---|
| Transcatheter Mitral And Tricuspid Therapies | $42M | $86M | $116M | $198M | $352M | $551M |
|---|
| $355M |
| Rest of World | $436M | $550M | $601M | $709M | $572M | $652M |
|---|
| UNITED STATES | $2.5B | $3.0B | $3.1B | $3.5B | $3.2B | $3.5B |
|---|
| $4.39B |
| +$38.30M |
| +0.88% |
| 2019 | $4.35B | +$625.20M | +16.79% |
| 2018 | $3.72B | +$287.50M | +8.37% |
| 2017 | $3.44B | +$471.60M | +15.91% |
| 2016 | $2.96B | +$470.00M | +18.85% |
